STOCK TITAN

Bond Selected by $300B+ Global Pharmaceutical Leader to Protect Employees

(Moderate)
(Neutral)
Tags

Bond (NASDAQ: OBAI) signed a phase 1 commercial agreement worth approximately $250,000 ARR with a global pharmaceutical company (market cap >$300B) covering 5,000 of the customer's 100,000 employees. The contract establishes a recurring revenue stream and includes an expansion pathway that could raise cumulative contract value beyond $1 million over time, supporting Bond's enterprise traction and scalable ARR growth.

The engagement deploys Bond's AI-powered Preventative Personal Security platform for multi-function workforce protection and positions the company for broader enterprise expansion.

Loading...
Loading translation...

Positive

  • New $250,000 ARR enterprise contract
  • Coverage of 5,000 employees across customer operations
  • Expansion pathway could exceed $1 million cumulative value
  • Commercial entry into a >$300B market-cap pharmaceutical leader

Negative

  • Initial contract covers only 5% of the customer's 100,000 employees
  • Initial $250,000 ARR is limited relative to potential scaled opportunity

News Market Reaction – OBAI

+0.95%
23 alerts
+0.95% Session close to close
+14.2% Peak Tracked
-19.2% Trough Tracked
$32.02M Market Cap
0.4x Rel. Volume

In the Feb 23 session, OBAI gained 0.95%, reflecting a mild positive market reaction. Argus tracked a peak move of +14.2% during that session. Argus tracked a trough of -19.2% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement establishes a new $250,000 ARR stream and a phase 1 deployment for 5,000 of a 100,...
Analysis

This announcement establishes a new $250,000 ARR stream and a phase 1 deployment for 5,000 of a 100,000-employee base at a $300B+ pharmaceutical company, with expansion potential beyond $1 million. It builds on earlier pilots with very large employers and municipalities. Investors may watch for evidence of upsell across the remaining workforce, additional enterprise wins, and how recurring revenue growth interacts with existing debt obligations and prior financing structures.

Key Figures

Initial ARR: $250,000 Expansion potential: $1 million Partner market cap: $300 billion+ +3 more
6 metrics
Initial ARR $250,000 Phase 1 commercial agreement annual recurring revenue
Expansion potential $1 million Potential cumulative contract value over time, subject to future agreements
Partner market cap $300 billion+ Market capitalization of global pharmaceutical customer
Employees covered initially 5,000 employees Initial workforce coverage under the agreement in the USA
Total workforce 100,000 employees Total global employee base of the pharmaceutical customer
New ARR stream $250,000 New recurring revenue stream added to Bond’s ARR base

Historical Context

4 past events · Latest: Feb 18 (Positive)
Pattern 4 events
Date Event Sentiment 24h Move Catalyst
Feb 18 Corporate rebranding Positive -12.4% Name change to Our Bond, Inc. to align brand with global expansion.
Feb 13 Enterprise pilot update Positive -26.4% Completion of one-year paid pilot and talks for >$10M annual rollout.
Feb 11 AI platform positioning Neutral -44.6% Highlighting AI-powered security as scalable alternative after abduction report.
Feb 05 Municipal pilot success Positive -42.4% Major city certifies Bond as sole supplier and indicates intent for citywide roll-out.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

All 4 recent news items with generally positive or neutral operational updates were followed by negative 24-hour price reactions, suggesting a pattern of selling into news.

Recent Company History

Over February 2026, OBAI reported several operational milestones, including a corporate name change, pilots with a major municipality and a nearly 1 million-employee U.S. employer, and positioning of its AI-powered security platform. Despite these seemingly constructive updates, 24-hour price reactions were negative after each release, with moves ranging from about -12% to over -44%. Today’s enterprise contract with a top global pharmaceutical company fits this pattern of positive news against a weak trading backdrop.

Key Terms

annual recurring revenue (arr), market capitalization, total addressable market (tam)
3 terms
annual recurring revenue (arr) financial
"Initial Contract Establishes New $250,000 Annual Recurring Revenue (ARR) Stream"
Annual Recurring Revenue (ARR) is the predictable amount of money a company expects to earn in a year from its ongoing services or subscriptions. It helps businesses understand their steady income stream, much like knowing how much rent they can count on each year, which is important for planning and growth.
market capitalization financial
"one of the world’s five largest pharmaceutical companies, an organization with a market capitalization exceeding $300 billion"
Market capitalization is the total market value of a company’s outstanding shares, calculated by multiplying the current share price by the number of shares issued. It gives a quick snapshot of a company’s size and how investors value it, influencing perceived risk, index membership, and roughly how much it might cost to buy the whole company — like using a sticker price to compare the relative size and price of different houses.
View in glossary
total addressable market (tam) financial
"contributing to Bond’s immense Total Addressable Market (TAM) encompassing virtually everyone with a smart phone"
Total addressable market (TAM) is an estimate of the total revenue opportunity available for a product or service if it captured 100% of its potential customers. Think of it as the size of the whole pizza a company could sell rather than the slice it currently has; investors use TAM to judge how big a business could grow, compare opportunities across companies, and decide whether a market is large enough to support meaningful returns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Initial Contract Establishes New $250,000 Annual Recurring Revenue (ARR) Stream With Expansion Potential Exceeding $1 Million

Agreement Reflects Continued Enterprise Revenue Momentum

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Our Bond, Inc. (“Bond”) (NASDAQ: OBAI), the creator of the world’s first AI-powered Preventative Personal Security platform adopted by leading multinational companies, today announced the execution of a phase 1 commercial agreement valued at approximately $250,000 with one of the world’s five largest pharmaceutical companies, an organization with a market capitalization exceeding $300 billion.

The agreement covers 5,000 of the customer’s 100,000 employees across various functions and locations, initially in the USA, as part of a 24/7 full workforce coverage protection concept. This establishes a new recurring revenue stream for Bond and marks the Company’s entry into a commercial relationship with a global healthcare industry leader. It also reflects further evidence that Bond is on the path to becoming a global standard of care for all employees – not only for executives – among leading global employers.

The engagement provides for deployment of Bond’s AI Powered Personal Security platform to support designated employee populations, with a clear expansion pathway that could increase cumulative contract value beyond $1 million over time, subject to additional scope and future agreements.

Expanding Annual Recurring Revenue Through Enterprise Adoption

The $250,000 agreement contributes to Bond’s growing Annual Recurring Revenue (ARR) base and reflects continued traction within large multinational enterprises.

The Company views initial enterprise engagements as foundational relationships designed to demonstrate operational value and support phased expansion across broader employee populations over time. Bond believes this structure enables scalable ARR growth within large organizations.

“Executing commercial agreements with global leaders is central to our global expansion and revenue growth strategy,” said Doron Kempel, Bond’s Founder and CEO. “We have been focused on adoption of the Bond services by the largest companies in the world, thus establishing a standard for all corporations to eventually follow. Such leading corporations like this pharmaceutical giant, typically start with a first wave of Bond coverage across employee demographics, from which they typically later gradually expand the Bond coverage to more or all employees. With each such agreement, Bond is nearing a tipping point of becoming a globally required security standard for preventatively protecting all employees 24/7 – effectively and affordably. This has not been feasible prior to Bond and its AI-Powered Preventative Personal Security Platform.”

Support for Diverse Use Cases Key Factor

Global pharmaceutical companies operate across global geographies, research facilities, field operations, manufacturing sites, and international corporate offices — presenting complex workforce protection challenges. Bond’s AI-powered platform delivers scalable, real-time preventative security protection is versatile and designed to address a broad diversity of threat situations across employee functions, geographies, and operating conditions. Corporations offer the Bond service to executives, their family members, and all types of employees: store, branch, lab, and clinic employees, sales and technical support personnel, drivers, nurses, social workers and well beyond. This broad applicability also means that while Bond’s focus is currently on corporations, there is great potential to include consumers in future go-to-market efforts.

Bond’s proven effectiveness saving lives and enhancing peace of mind, massive international scalability, affordability, privacy preservation, and versatility across demographics and risk types are at the core of the Bond revolution and differentiation, contributing to Bond’s immense Total Addressable Market (TAM) encompassing virtually everyone with a smart phone or other connected device globally. Bond has also been recognized by public sector entities as a sole supplier of AI-Powered Preventative Personal Security with 24/7 Live Security Agents, removing the need for competitive tender processes.

The Company believes continued successful execution within globally recognized enterprises may accelerate broader industry adoption and support further expansion of its enterprise revenue pipeline.

About Bond

Bond is an international company headquartered in New York City — with command centers around the world — that is redefining personal security through its AI-powered Preventative Personal Security platform. The company has invested more than $100 million to date in its technology, operations, and global expansion.

Bond is trusted by leading corporations, cities, and universities, and has already supported more than 1.4 million security service requests, including over 10,000 emergencies and life-saving interventions. Bond operates in 28 countries and growing, positioning itself as a new global standard for personal security and peace of mind. Additional information about the Company is available at: www.ourbond.com.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading “Risk Factors” in our most recent Registration Statement on Form S-1, under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K, or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC, copies of which are available on the SEC's website at www.sec.gov. TG-17, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise that occur after the date of this release, except as required by law.

Contact:
Crescendo Communications, LLC
212-671-1020
OBAI@crescendo-ir.com


FAQ

What did Bond announce on February 23, 2026 about a new customer contract (OBAI)?

Bond announced a phase 1 commercial agreement worth about $250,000 ARR with a global pharma customer. According to Bond, the contract covers 5,000 of 100,000 employees and includes a clear expansion pathway that could raise cumulative value beyond $1 million.

How many employees will Bond protect under the new OBAI agreement and where?

The agreement initially covers 5,000 employees, primarily in the USA. According to Bond, deployment targets diverse functions and locations as part of 24/7 workforce protection with phased expansion potential across the customer's global footprint.

What is the potential revenue upside from Bond's new contract announced Feb 23, 2026 (OBAI)?

The contract starts at about $250,000 ARR with expansion potential exceeding $1 million over time. According to Bond, additional scope and future agreements could increase cumulative contract value beyond that threshold.

How does the new pharmaceutical customer contract affect Bond's ARR (OBAI)?

The $250,000 agreement establishes a new recurring revenue stream contributing to ARR growth. According to Bond, the engagement is foundational and intended to support phased, scalable expansion across larger employee populations over time.

Does the Feb 23, 2026 OBAI deal indicate enterprise traction for Bond's platform?

Yes — the agreement represents enterprise traction with a global, >$300B market-cap pharmaceutical leader. According to Bond, this commercial entry supports broader adoption and a pathway toward larger, multi-phase deployments.

What use cases will Bond's AI-powered platform cover under the new OBAI agreement?

Bond's platform will provide 24/7 preventative personal security for executives and diverse employee types. According to Bond, use cases include field operations, labs, manufacturing, corporate offices, and frontline roles such as nurses and drivers.